Articles tagged with Schizophrenia
The center will investigate the link between schizophrenia and dysfunctional brain N-methyl-D-aspartate receptors (NMDA). Researchers aim to identify pre-symptomatic individuals in adolescence to intervene before disease effects take hold. The grant also supports a summer undergraduate research program.
Case Western Reserve University researchers are using pluripotent stem cells to study schizophrenia and gain a better understanding of the complex disease. The study aims to characterize brain cell function in adolescent patients with schizophrenia, with the goal of deciphering the underlying cause of the condition.
A Sydney study finds that stranger homicides by people with schizophrenia are extremely rare and unpredictable events. The research suggests that providing earlier treatment for schizophrenia can prevent such tragic events.
Schizophrenia is a heterogeneous syndrome with substantial variation in symptomatology and life history. A paradigm shift in research focuses on identifying critical domains of pathology, such as positive and negative symptoms, cognitive impairment, and impaired cognition. This shift aims to improve treatment efficacy by targeting spec...
Researchers at Columbia University Irving Medical Center have identified an area of the brain involved in the earliest stages of schizophrenia. Activity in this region, known as the CA1 subfield, may help predict disease progression and provide opportunities for more targeted drug development to block the mechanism.
A systematic review of 20 studies found that individuals with schizophrenia are at increased risk of violence, but this risk is greatly outweighed by the effect of substance abuse. Substance abuse significantly increases the risk of violence for those with a psychotic illness, similar to those without a psychotic illness.
Researchers created a mouse model with low kalirin levels that developed schizophrenia symptoms as an adolescent, mimicking human delayed onset. The study suggests stimulating kalirin activity could help alleviate cognitive symptoms, offering new treatment direction.
The NIMH is launching a large-scale research project to explore the effectiveness of early and aggressive treatment in reducing symptoms of chronic schizophrenia. The Recovery After an Initial Schizophrenia Episode (RAISE) project aims to develop and test interventions that incorporate diverse treatment approaches and are tailored to i...
Researchers aim to develop an optimal early intervention strategy to treat first episode psychosis, reducing disability and mortality. The Recovery After Initial Schizophrenic Episode (RAISE) study will test culturally appropriate interventions in community-based sites.
Dr. Nichols' approach combines discovery studies with functional and behavioral studies in two models to determine how mental disorders like psychosis and schizophrenia develop. He aims to identify abnormally functioning genes and proteins that may represent novel therapeutic targets for neuropsychiatric disorders.
A study found that clozapine, restricted due to safety concerns, is associated with lower mortality compared to other antipsychotics. Long-term use of any antipsychotic reduces mortality by around 20%, indicating restrictions may have caused thousands of extra deaths worldwide.
Researchers aim to create a brain map that can help diagnose early-stage schizophrenia and guide more effective treatment. The study, led by Northwestern University, uses topographical brain maps to compare the structures of individuals with schizophrenia to those without, hoping to identify key differences in brain function.
Researchers found genetic variations on chromosome 6 associated with higher risk of schizophrenia. This discovery may lead to new treatments for autoimmune disorders and improve existing treatments.
Genome-wide studies identify a vast array of genetic variation that may account for at least one third of the genetic risk for schizophrenia. The studies found a shared chromosomal neighborhood between schizophrenia and bipolar disorder, implicating an area of Chromosome 6 in immunity and gene expression regulation.
A recent study supports multiple genetic contributions to schizophrenia and bipolar disorder, explaining at least a third of the risk of inheriting these diseases. The research found common genetic variants associated with both conditions.
Researchers identified a significant association between gene variations on chromosome 6 and schizophrenia risk. The study, combining data from 27,000 individuals, found evidence of immune function's potential role in the disease.
A multi-national group of investigators discovered that nearly a third of schizophrenia's genetic basis may be attributed to thousands of common genetic variants. These variants add up to a significant risk for developing both schizophrenia and bipolar disorder.
Researchers have identified a connection between the immune system and schizophrenia, finding genetic variations that disrupt brain development, memory, and cognition. The study's findings hold promise for developing new treatments targeting specific molecular mechanisms involved in the disorder.
People with schizophrenia are at a higher risk of dying from all causes, including cancer, due to factors like smoking and delayed diagnosis. Cancer mortality rates among schizophrenic patients are significantly higher than those in the general population, particularly for women.
A UCLA study reveals that adolescents at high risk for schizophrenia show altered brain development, including reduced white matter integrity. This alteration can predict future functional decline and may be key to identifying individuals who need more treatment.
Researchers have discovered a novel approach for treating cognitive impairments associated with schizophrenia by preventing the inactivation of D-serine. This method enhances the efficacy of D-serine, a previously used treatment, and may lead to improved therapeutic outcomes.
A new clinical discussion tool, GAIN, has been developed to help physicians discuss potential reasons for using long-acting injectable antipsychotic therapies with patients. The tool addresses barriers such as needle phobia and stigma, aiming to increase patient acceptance and adherence.
Researchers found no significant increase in violent crime among people with schizophrenia, contrary to previous assumptions. The study suggests that substance abuse co-occurring with schizophrenia is a key factor contributing to violence.
A study published in JAMA found that substance abuse increases the risk of violent crime in individuals with schizophrenia, with a 4.4-fold increased risk for those with comorbid substance abuse. The study also suggests that current practice for violence risk assessment and management may need review.
New studies demonstrate RISPERDAL CONSTA (risperidone) Long-Acting Treatment significantly improves clinical and functional outcomes for patients with schizophrenia. The treatment reduced rates of rehospitalization among patients, especially those with complex medical histories.
Researchers found significant cognitive problems exist in first-episode schizophrenia, affecting work, study, and social life. Early diagnosis may aid treatment and improve prognosis.
Researchers have identified a previously unknown form of potassium channel, Isoform 3.1, implicated in schizophrenia and linked to abnormal brain activity. Inhibiting this protein may correct disorganized brain activity without cardiac side effects associated with existing antipsychotic medications.
Researchers have identified a genetic variant that impairs communication within the brain, increasing the risk of schizophrenia and manic depression. The study found altered brain activity patterns, particularly between the dorsolateral prefrontal cortex and other regions.
The Medical College of Georgia is part of a large national study examining the genes of 10,000 patients with schizophrenia and 10,000 healthy individuals. The study aims to pinpoint variations that can improve disease diagnosis and treatment.
Scientists have discovered a compound that selectively targets the M1 receptor, implicated in diseases like AD and schizophrenia. This finding holds promise for developing an effective treatment with minimal side effects.
A study by Nicole Lauzon and Dr. Steven Laviolette found specific receptors in the brain can control emotional significance and memory formation for traumatic events, offering new therapeutic treatments for psychiatric disorders like Schizophrenia and PTSD.
A specific DNA change has been identified as a potential mechanism for developing schizophrenia. The research found that the altered gene increases expression in cells grown in culture, echoing findings in postmortem brain samples from individuals with schizophrenia.
Patients with schizophrenia can correctly identify a 'hollow mask' illusion, which may be related to their brains disconnecting visual information from internal thoughts. The study also found that cannabis users are less deceived by the illusion, suggesting a possible link between THC and brain connectivity.
Researchers discovered a significant link between schizophrenia and type 2 diabetes in a study of 50 people newly-diagnosed with schizophrenia. The study found that 16% of participants had either diabetes or abnormal glucose metabolism rates.
Researchers have identified a connection between daily cannabis consumption and the appearance of psychosis and schizophrenia in subjects with good premorbid performance. The study found that 66% of patients with normal neurodevelopment admitted to daily cannabis use, while 43% of those with abnormal neurodevelopment also used cannabis.
A study by MIT researchers found that inhibiting a key brain enzyme in mice reversed schizophrenia-like symptoms, offering potential new drug treatments. The discovery provides insight into the DISC1 gene's role in regulating GSK3B activity and its impact on neural stem cells.
Scientists at the University of Leeds have discovered a link between toxoplasmosis and schizophrenia, suggesting that the parasite affects dopamine production in the brain. The study provides new insights into the development of schizophrenia and its potential connections to other neurological disorders.
Researchers identified 49 genes involved in cell-to-cell signalling in the brains of schizophrenia patients compared to controls, supporting the theory that faulty signalling is involved in the disease. The findings could lead to new ways of diagnosing and treating the condition.
Researchers will map planum temporale's functional organization to better understand its role in language abilities and disorders. The study aims to find connections between the brain region and conditions such as autism, schizophrenia, and perfect pitch.
Researchers discovered that mice lacking neuregulin develop dendritic spine abnormalities and exhibit hallmarks of schizophrenia, supporting the hypothesis that glutamatergic neurons play a crucial role. The study suggests that developmental defects in brain structure may contribute to schizophrenia's onset.
A UK survey found that only 30% of mental health workers discuss sexual health issues with service users, despite 80% agreeing it's an important part of their role. The study also revealed low levels of awareness about HIV risks among people with schizophrenia, leading to concerns about infection rates and staff safety.
A new study reveals that large structural DNA changes, known as copy number variants, may be responsible for schizophrenia. Researchers found eight deletions in patients' genomes, two of which were newly identified, suggesting that these rare variations could be causative.
Schizophrenia can be detected early by identifying physical markers in the brain, according to Prof. Talma Hendler's groundbreaking work on facial recognition and brain imaging. By analyzing brain activity in response to unusual emotional faces, researchers hope to develop more effective treatments.
Researchers identified three genetic variants associated with delusions in people with schizophrenia, located within the neuregulin 3 gene on chromosome 10. The study suggests that this gene may contribute to the development of delusions and other symptoms of the condition.
Research suggests that schizophrenia patients' reduced non-verbal expressivity is linked to poor social skills and an inability to accurately imagine others' thoughts and feelings. This impairment contributes to difficulties in conversation and social interactions, making it challenging for people with schizophrenia to engage with others.
A new MIT study found that schizophrenia is linked to an overactive 'default mode' brain system involved in self-reflection. This hyperactive system causes patients to have an exaggerated focus on themselves, leading to cognitive and psychological symptoms.
A global study reveals that people with schizophrenia experience and expect significant discrimination in various aspects of life, including employment, relationships, and social interactions. The study, which analyzed data from 27 countries, found that negative experienced discrimination was common across all domains.
A large-scale study of 9 million Swedish individuals reveals that bipolar disorder and schizophrenia share common genetic causes, with heritability rates of 64% and 59%, respectively. This finding challenges the long-held distinction between the two conditions, suggesting a reappraisal of their diagnostic entities.
Research suggests that autism and schizophrenia may stem from similar physical abnormalities caused by disruptions in early organogenesis, typically between 20-40 days after fertilization. This developmental stage is critical in shaping the body's development, and errors during this period can lead to various mental health disorders.
Researchers identified a faulty brain circuit and developed an experimental agent that improves working memory and EEG signals in people with schizophrenia. The study found the drug MK-0777 to be well-tolerated, but further trials are needed to verify its value.
Elevated levels of kynurenic acid in the brain have been linked to problem-solving deficits in patients with schizophrenia. The finding suggests that drugs targeting this compound could be used to treat cognitive impairments associated with the disorder.
A collaborative study reveals how interactions between common gene variants affect brain function in schizophrenia patients, particularly in working memory. The findings suggest that combining these genetic variations may lead to reduced cortical activity, making them potential new targets for treatments.
Researchers at the University of Pittsburgh have identified the orbitofrontal cortex as a promising target for developing new antipsychotic drugs to treat schizophrenia. The study found that this brain region responds to both dopamine and glutamate, neurotransmitters linked to schizophrenia.
Researchers at Newcastle University have identified a key brain link that causes schizophrenia, revealing NMDA receptors play a critical role in modifying brain oscillations. Optimizing receptor function could lead to new treatment approaches for the mental illness, affecting one in 100 people.
Research suggests that birth hypoxia may contribute to the development of schizophrenia by reducing brain-derived neurotrophic factor (BDNF) levels. The study found a significant decrease in BDNF among individuals who later developed schizophrenia, highlighting the importance of maternal health during pregnancy.
Researchers found that deleting the gene for glutamate transporter EAAT1 leads to increased responses to NMDA receptor antagonist MK-801, resulting in schizophrenia-like features in mice. The study suggests a promising new class of glutamate-targeting antipsychotic treatments may help correct these abnormalities.
Research suggests that cerebral inflammation and microglia activation contribute to schizophrenia development. Anti-inflammatory agents targeting activated microglia may provide a new treatment option for the condition.
Researchers have identified three new candidate genes for schizophrenia that may contribute to a better understanding of the disease. These genes are associated with brain function and are present in only 1% of schizophrenia patients, suggesting they play a significant role in its development.
NARSAD recognizes six scientists whose groundbreaking research has led to significant strides in understanding and treating mental illness. The 2008 prize winners include experts in schizophrenia, bipolar disorder, depression, childhood disorders, and cognitive neuroscience.
Researchers found that brain-derived neurotrophic factor (BDNF) levels can indicate impending relapse in schizophrenia patients. BDNF levels may drop even before symptoms worsen, suggesting a potential biomarker for early intervention and treatment adjustment.